help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on July 24, 2008, doi:10.1164/rccm.200711-1657OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200711-1657OCv1
178/8/876    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hopkins, P.
Right arrow Articles by Nissen, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hopkins, P.
Right arrow Articles by Nissen, M.
American Journal of Respiratory and Critical Care Medicine Vol 178. pp. 876-881, (2008)
© 2008 American Thoracic Society
doi: 10.1164/rccm.200711-1657OC


Original Article

Human Metapneumovirus in Lung Transplant Recipients and Comparison to Respiratory Syncytial Virus

Peter Hopkins1, Keith McNeil1, Fiona Kermeen1, Michael Musk1, Emily McQueen2, Ian Mackay2,3, Terry Sloots2 and Michael Nissen2

1 Queensland Heart-Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Australia; 2 Queensland Paediatric Infectious Diseases Laboratory, Royal Children's Hospital, Brisbane, Australia; and 3 Clinical Medical Virology Centre, University of Queensland, Brisbane, Australia

Correspondence and requests for reprints should be addressed to Dr. Peter Hopkins, M.D., Department of Respiratory Medicine, The Prince Charles Hospital, Rode Road, Chermside, Brisbane, Australia 4032. E-mail: peterwakatipu{at}hotmail.com

Rationale: Human metapneumovirus is a newly described virus isolated in 2001 from children with acute respiratory viral infection. It has subsequently been reported globally, although there are limited data in lung transplant recipients.

Objectives: To prospectively analyze whether human metapneumovirus was circulating in our adult lung transplant community and assess the morbidity of this infection and to compare the clinical presentation and outcome after intravenous ribavirin of human metapneumovirus with that of respiratory syncytial virus (RSV).

Methods: Lung transplant patients with clinical features of respiratory viral infection underwent nasopharyngeal aspirates. Patients with a positive specimen for RSV or human metapneumovirus by reverse transcriptase–polymerase chain reaction analysis and graft dysfunction received intravenous ribavirin and pulse steroid therapy.

Measurements and Main Results: Eighty-nine patients had 199 visits for aspirate studies. A viral cause was determined for 62 visits in 47 patients (19 human metapneumovirus, 18 RSV, 13 parainfluenza, 9 influenza A, 2 adenovirus, and 1 influenza B). A significant percentage of patients with metapneumovirus (63%) and RSV (72%) developed graft dysfunction, with average declines in FEV1 of 30 ± 12.4% and 25.9 ± 11.2%, respectively. In these patients, bronchiolitis obliterans syndrome onset or progression occurred in no patients with human metapneumovirus compared with 5 of 13 (38%) patients with RSV at 6 months.

Conclusions: Human metapneumovirus is a leading cause of acute respiratory tract illness in lung transplant recipients. The incidence and clinical spectrum at presentation are similar to RSV, although the latter seems to be associated with a higher risk of chronic rejection. We recommend testing of nasopharyngeal aspirates for human metapneumovirus with polymerase chain reaction to assess local epidemiologic patterns.

Key Words: respiratory • virus • solid organ transplant


AT A GLANCE COMMENTARY

Scientific Knowledge on the Subject
Acute respiratory viral infection in lung transplant recipients often has no cause identified on standard viral polymerase chain reaction tests, suggesting the presence of unidentified pathogens. Human metapneumovirus is a recently described paramyxovirus capable of infecting the respiratory tract, although few data exist on the epidemiology and response to therapy in such high-risk cohorts.

What This Study Adds to the Field
Human metapneumovirus among lung transplant recipients detection in lung transplant recipients and their response to ribavirin therapy. This virus was as frequent in occurrence as respiratory syncytial virus from nasopharyngeal aspirates but was not associated with a higher risk of chronic rejection.

 



This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
V. N. Lama
Update in Lung Transplantation 2008
Am. J. Respir. Crit. Care Med., May 1, 2009; 179(9): 759 - 764.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2008 American Thoracic Society
  CCM abstracts